NeuroBo Pharmaceuticals (NRBO) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and NeuroBo Pharmaceuticals (NASDAQ:NRBO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, community ranking, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

Does the media prefer CASI or NRBO?

In the previous week, CASI Pharmaceuticals had 1 more articles in the media than NeuroBo Pharmaceuticals. MarketBeat recorded 4 mentions for CASI Pharmaceuticals and 3 mentions for NeuroBo Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.50 beat NeuroBo Pharmaceuticals' score of 0.00 indicating that CASI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CASI Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroBo Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, CASI or NRBO?

CASI Pharmaceuticals has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, NeuroBo Pharmaceuticals has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500.

Do institutionals & insiders have more ownership in CASI or NRBO?

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 1.4% of NeuroBo Pharmaceuticals shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by insiders. Comparatively, 1.1% of NeuroBo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Do analysts prefer CASI or NRBO?

CASI Pharmaceuticals presently has a consensus price target of $6.00, indicating a potential upside of 14.29%. NeuroBo Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 316.67%. Given NeuroBo Pharmaceuticals' higher possible upside, analysts clearly believe NeuroBo Pharmaceuticals is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
NeuroBo Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better earnings and valuation, CASI or NRBO?

NeuroBo Pharmaceuticals has lower revenue, but higher earnings than CASI Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$33.88M	2.40	-$26.94M	-$2.23	-2.35
NeuroBo Pharmaceuticals	N/A	N/A	-$12.47M	N/A	N/A

Does the MarketBeat Community favor CASI or NRBO?

CASI Pharmaceuticals received 173 more outperform votes than NeuroBo Pharmaceuticals when rated by MarketBeat users. However, 75.00% of users gave NeuroBo Pharmaceuticals an outperform vote while only 50.25% of users gave CASI Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
CASI Pharmaceuticals	Outperform Votes 200 50.25%	Underperform Votes 198 49.75%
NeuroBo Pharmaceuticals	Outperform Votes 27 75.00%	Underperform Votes 9 25.00%

Is CASI or NRBO more profitable?

NeuroBo Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -143.18%. CASI Pharmaceuticals' return on equity of -181.52% beat NeuroBo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-143.18%	-181.52%	-45.72%
NeuroBo Pharmaceuticals	N/A	-189.12%	-122.31%

Summary

CASI Pharmaceuticals beats NeuroBo Pharmaceuticals on 9 of the 13 factors compared between the two stocks.